Obinutuzumab in multidrug-resistant hairy cell leukemia

Ann Hematol. 2016 Jan;95(2):351-2. doi: 10.1007/s00277-015-2520-y. Epub 2015 Oct 7.

Authors

Jan-Paul Bohn¹, Ella Willenbacher², Michael Steurer²

Affiliations

¹ Department of Internal Medicine V, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria. Jan-Paul.Bohn@i-med.ac.at.
² Department of Internal Medicine V, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.

PMID: 26446506
DOI: 10.1007/s00277-015-2520-y

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Drug Resistance, Multiple / drug effects*
Drug Resistance, Neoplasm / drug effects*
Humans
Leukemia, Hairy Cell / diagnosis
Leukemia, Hairy Cell / drug therapy*
Male

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
obinutuzumab